Pezo RC, Bedard PL. Definitions: Translational and Personalised Medicine, Biomarker and Pharmacodynamics. En: Tortora G, Sessa C, Scarpa A, Banerjee S. ESMO Handbook of Translational Research. 1st. Lugano: ESMO Press; 2015.p. 1-12.

Johnson TM. Perspective on precision medicine in oncology. Pharmacotherapy. [Internet]. 2017 [citado 23/8/2020]; 37(9):988-989. Disponible en: https://doi.org/10.1002/phar.1975.

Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. [Internet]. 2015 [citado 23/8/2020]; 24(Suppl 2):S26-S35. Disponible en: http://dx.doi.org/10.1016/j.breast.2015.07.008.

Krzyszczyk P, Acevedo A, Davidoff E, Timmins LM, Marrerro Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). [Internet]. 2018 [citado 23/8/2020]; 6(3-4):79-100. Disponible en: https://doi.org/10.1142/S2339547818300020.

Zhang W, Wang J, Menon S. Advancing cancer drug development through precision medicine and innovative designs. J Biopharm Stat. [Internet]. 2018 [citado 23/8/2020]; 28(2):229-244. Disponible en: https://doi.org/10.1080/10543406.2017.1402784.

White NW, Kulasingam V, Diamandis EP, Yousef GM. Tsongalis GJ, Vermeulen L, et al. The use of targeted therapies for precision medicine in oncology. Clin Chem. [Internet]. 2016 [citado 23/8/2020]; 62(12):1556-1564. Disponible en: https://academic.oup.com/clinchem/article-abstract/62/12/1556/5612042

Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, et al. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Sem Oncol. [Internet]. 2018 [citado 23/8/2020]; 45(1-2):18-26. Disponible en: https://doi.org/10.1053/j.seminoncol.2018.04.008